title: MTHFR polymorphisms in relation to ovarian cancer risk.
abstract: OBJECTIVE
  Folate has been hypothesized to influence carcinogenesis due to its dual role in DNA methylation, which regulates gene expression, and synthesis of purine and thymidylate, which is vital for DNA repair. Thus, we examined ovarian cancer risk in relation to two functional polymorphisms (C677T and A1298C) in the MTHFR gene.
  
  
  METHODS
  We genotyped the C677T (rs1801133) and A1298C (rs1801131) MTHFR polymorphisms in 1642 cases and 2068 controls from three studies, the New England Case Control Study (NEC), Nurses' Health Study (NHS), and Mayo Clinic Ovarian Cancer Case Control Study (MAY).
  
  
  RESULTS
  Overall, we observed no association between either SNP and ovarian cancer risk (pooled C677T p(trend)=0.59 and A1298C p(trend)=0.58). Significant associations (C677T p(trend)=0.001, A1298C p(trend)=0.02) between these MTHFR SNPs and serous ovarian cancer risk were observed in the NEC study, but were not replicated in the NHS and MAY studies.
  
  
  CONCLUSIONS
  MTHFR SNPs C677T and A1298C are not associated with ovarian cancer risk. Our results highlight the need for validation of genetic findings.
authors.affiliation: Ob-Gyn Epidemiology Center, Brigham and Women's Hospital, Boston, MA 02115, USA. kterry@partners.org
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Terry
authors.forename: Shelley S
authors.initials: SS
authors.lastname: Tworoger
authors.forename: Ellen L
authors.initials: EL
authors.lastname: Goode
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Gates
authors.forename: Linda
authors.initials: L
authors.lastname: Titus-Ernstoff
authors.forename: Linda E
authors.initials: LE
authors.lastname: Kelemen
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Sellers
authors.forename: Susan E
authors.initials: SE
authors.lastname: Hankinson
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Cramer
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality; D020641:Polymorphism, Single Nucleotide; D014481:United States / Q000453:epidemiology
chemical_list: D042965:Methylenetetrahydrofolate Reductase (NADPH2)
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1611-21
references.pmid: 12496052
references.citation: J Natl Cancer Inst. 2004 Mar 17;96(6):434-42
references.pmid: 15026468
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):281-7
references.pmid: 17301261
references.citation: Genet Med. 2002 Mar-Apr;4(2):45-61
references.pmid: 11882781
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):2047-52
references.pmid: 15756031
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1198-203
references.pmid: 15894672
references.citation: Nat Genet. 2001 Nov;29(3):306-9
references.pmid: 11600885
references.citation: Eur J Cancer. 2000 Dec;36(18):2313-6
references.pmid: 11094304
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):397-404
references.pmid: 18268124
references.citation: Eur J Cancer Prev. 2006 Dec;15(6):511-5
references.pmid: 17106331
references.citation: Breast Cancer Res Treat. 2007 Sep;104(3):299-308
references.pmid: 17063264
references.citation: Cancer. 1996 Mar 1;77(5):917-23
references.pmid: 8608484
references.citation: Pharmacogenetics. 2002 Jun;12(4):339-42
references.pmid: 12042673
references.citation: Am J Epidemiol. 2006 Jun 15;163(12):1101-11
references.pmid: 16554344
references.citation: J Natl Cancer Inst. 2000 Jul 19;92(14):1151-8
references.pmid: 10904088
references.citation: J Nutr. 1999 Sep;129(9):1656-61
references.pmid: 10460200
references.citation: Br J Nutr. 2000 Jun;83(6):593-6
references.pmid: 10911766
references.citation: Cancer Res. 1997 Mar 15;57(6):1098-102
references.pmid: 9067278
references.citation: Eur J Cancer. 2009 May;45(8):1443-9
references.pmid: 19223177
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):89-100
references.pmid: 20056627
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):505-12
references.pmid: 12050090
references.citation: Am J Epidemiol. 1994 Dec 1;140(11):1016-9
references.pmid: 7985649
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1753-9
references.pmid: 17855693
references.citation: Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5606-11
references.pmid: 11929966
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):825-9
references.pmid: 10498402
references.citation: Am J Epidemiol. 1984 May;119(5):837-9
references.pmid: 6720679
references.citation: J Natl Cancer Inst. 2004 Mar 3;96(5):396-402
references.pmid: 14996861
references.citation: Cancer Causes Control. 2004 Dec;15(10):1085-93
references.pmid: 15801492
references.citation: J Natl Cancer Inst. 1993 Jun 2;85(11):875-84
references.pmid: 8492316
references.citation: Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):649-54
references.pmid: 8547832
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1781-9
references.pmid: 18628432
references.citation: JAMA. 1999 May 5;281(17):1632-7
references.pmid: 10235158
references.citation: Nat Genet. 2009 Sep;41(9):996-1000
references.pmid: 19648919
references.citation: Semin Oncol. 1992 Apr;19(2 Suppl 4):46-50
references.pmid: 1532459
references.citation: J Mol Med (Berl). 2001 Sep;79(9):522-8
references.pmid: 11692165
references.citation: Ann Oncol. 2001 Nov;12(11):1589-93
references.pmid: 11822759
references.citation: Anticancer Res. 1997 Sep-Oct;17(5A):3671-4
references.pmid: 9413221
references.citation: Int J Cancer. 2002 Dec 10;102(5):545-7
references.pmid: 12432561
references.citation: Epidemiology. 2001 Jul;12(4):420-8
references.pmid: 11416780
references.citation: Am J Hum Genet. 1998 May;62(5):1044-51
references.pmid: 9545395
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1331-6
references.pmid: 15298954
references.citation: Clin Cancer Res. 2003 May;9(5):1611-5
references.pmid: 12738713
references.citation: J Nutr. 2003 Jun;133(6):1937-42
references.pmid: 12771342
references.citation: Nat Genet. 1995 May;10(1):111-3
references.pmid: 7647779
references.citation: Lancet. 2003 Mar 8;361(9360):865-72
references.pmid: 12642066
references.citation: Cancer Res. 2008 Apr 1;68(7):2498-506
references.pmid: 18381459
references.citation: Thromb Haemost. 1997 Jul;78(1):523-6
references.pmid: 9198208
references.citation: Am J Epidemiol. 2005 Mar 1;161(5):442-51
references.pmid: 15718480
references.citation: Epidemiology. 1998 May;9(3):350-4
references.pmid: 9583430
references.citation: Mol Genet Metab. 1998 Jul;64(3):169-72
references.pmid: 9719624
references.citation: Cancer Causes Control. 2000 Dec;11(10):965-74
references.pmid: 11142531
references.citation: Cancer Res. 1996 Nov 1;56(21):4862-4
references.pmid: 8895734
references.citation: Int J Cancer. 2007 Nov 15;121(10):2225-32
references.pmid: 17471564
references.citation: Clin Cancer Res. 2010 Feb 1;16(3):995-1007
references.pmid: 20103664
references.citation: Cancer Detect Prev. 2005;29(2):146-54
references.pmid: 15829374
references.citation: Breast Cancer Res Treat. 2007 Dec;106(2):263-71
references.pmid: 17260091
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):285-92
references.pmid: 14973104
references.citation: Carcinogenesis. 1997 Dec;18(12):2307-11
references.pmid: 9450474
references.citation: Breast Cancer Res Treat. 2010 Sep;123(2):549-55
references.pmid: 20143151